to-BBB technology will be used by MedImmune to evaluate brain drug delivery mechanism
to-BBB and MedImmune are starting a research program to evaluate to-BBB’s proprietary G-Technology™ to safely deliver drugs to the brain.
Many brain diseases cannot be treated with today’s disease modifying biologics due to the presence of the neuroprotective blood-brain barrier (BBB). to-BBB’s G-Technology is designed for safe brain delivery of different classes of drugs by formulating these drugs into proprietary glutathione coated liposomes. The G-Technology has shown proof of concept in different disease models for pain, viral encephalitis and brain tumors, based on which MedImmune will now evaluate the technology in its own pharmacodynamic models.
“We are looking forward to working with MedImmune” says Pieter Gaillard, CSO of to-BBB “The project will be of great value to further validate our brain delivery platform and work towards therapies for devastating brain diseases”.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.